Royalty Pharma plc - Class A

Research Royalty Pharma plc - Class A (RPRX) on Bullrun: valuation model: 20.6% overvalued, market cap USD 25.31B, P/E 29.9, dividend yield 1.6%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerRPRX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal20.6% overvalued
• Market capUSD 25.31B
• P/E29.9
• Dividend yield1.6%
• Financial periodFY2025
• RevenueUSD 2.38B
• Revenue growth5.1%
• Net incomeUSD 770.95M

Valuation Snapshot

Bullrun's latest valuation model marks Royalty Pharma plc - Class A as 20.6% overvalued; latest market cap is USD 25.31B; P/E is 29.9; dividend yield is 1.6%.

About Royalty Pharma plc - Class A

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.

Frequently asked questions

Is Royalty Pharma plc - Class A overvalued or undervalued?

Bullrun's valuation model currently marks Royalty Pharma plc - Class A as 20.6% overvalued.

What is Royalty Pharma plc - Class A's market cap?

Royalty Pharma plc - Class A's market capitalization is USD 25.31B.

What is Royalty Pharma plc - Class A's P/E ratio?

Royalty Pharma plc - Class A's price-to-earnings (P/E) ratio is 29.9.

Does Royalty Pharma plc - Class A pay a dividend?

Royalty Pharma plc - Class A has a dividend yield of 1.6%.

What does Royalty Pharma plc - Class A do?

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.